Innovassynth Technologies (india) Ltd · BSE:INOVSYNTH
Innovassynth Technologies (india) — Q2 FY27 Earnings Presentation
16 slides from Innovassynth Technologies (india)'s earnings presentation, Nov 2, 2026
Slide 1: Cover letter to BSE
Date: November 02, 2026 To, Manager, Corporate Relationship Department, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001 Scrip Code: 533315 Dear Sir/Madam, Sub: Investor Presentation With reference to the subject, please find enclosed the Investor Presentation for the quarter and h
Slide 2: Investor Presentation Q2FY27
Investor Presentation Q2FY27 2-November-2026
Slide 3: Disclaimer
Disclaimer “This presentation has been prepared by Innovassynth Technologies India Limited (“Company”) (formerly known as Innovassynth Investments Limited). The presentation aims to cover key financial and business highlights. This presentation and some statements herein may be forward-looking state
Slide 4: Executive Summary and Financials
Executive Summary and Financials 3
Slide 5: Executive Summary: Performance Update and Outlook
Executive Summary Performance Update and Outlook • EBITDA was impacted primarily by the spillover of certain sales scheduled for Q2 into the subsequent quarter and, to some extent, by higher costs of certain raw materials due to geopolitical developments in West Asia. • Given the inherent nature of
Slide 6: Executive Summary: Execution Highlights & Growth Drivers
Executive Summary Execution Highlights & Growth Drivers • Life Sciences capacity expansion largely remains on track and is expected to enhance our ability to support future customer requirements and growth opportunities. • We are undertaking debottlenecking initiatives across manufacturing facilitie
Slide 7: H1 FY27 Financial Performance – Comparative Analysis
H1 FY27 Financial Performance – Comparative Analysis Revenue EBIDTA PAT 12,000 2,000 1000 823 10,688 1,664 500 10,000 1,000 0 8,000 -500 0 -1000 6,000 -1,000 -1500 4,000 2,993 -2000 2,000 -2,000 -2500 -3000 0 -2,663 -3,132 -3,000 -3500 H1 FY 27 H1 FY 26 H1 FY 27 H1 FY 26 H1 FY 27 H1 FY 26 EPS Net Wo
Slide 8: Strategic Growth & Business Development Highlights
Strategic Growth & Business Development Highlights Open Order Book Amount in INR Crores Life Sciences Specialty Chemicals CDMO Grand Total INR ~73 INR ~10 INR ~55 INR ~137 Major orders from USA/EU Strong portfolio and Confirmed requirements based companies, with custom product shared by large global
Slide 9: Profit and Loss Statement
Profit and Loss Statement Particulars Quarter Ended 6 Months Ended Year Ended 30-Sep-26 30-Jun-26 30 Sep-25 30-Sep-26 30-Sep-25 31-Mar-26 Unaudited Unaudited Unaudited Unaudited Unaudited Audited Revenue from operations 4,755 5,599 1,728 10,353 2,955 10,235 Operating Expenses (4,587) (4,102) (2,838)
Slide 10: Balance Sheet
Balance Sheet Amount in INR Lakhs Particulars Q2 FY26 Q2 FY25 Particulars Q2 FY26 Q2 FY25 Assets Equity and Liabilities Non-Current Assets Equity Property, Plant and Equipment 12,395 12,161 Equity, Shared Capital 9,286 7,545 Right of use assets 706 786 Other equity 7,888 1,904 Capital work-in-progre
Slide 11: Company Overview
Company Overview 10
Slide 12: Business Model
Business Model Innovassynth has 3 business units Contract Research Life Sciences & Nucleosides Specialty Chemicals Development and Manufacturing Exports Led Business : ~90% of revenue from global geographies with key focus on USA & EU Our Life Sciences & Specialty Chemicals segments focus on develop
Slide 13: Innovassynth – At a Glance
Innovassynth – At a Glance • Manufacturing plant in 60+ acres at Khopoli with 8 units • 60 fume hoods catering to custom • 10+ Line with total reaction Manufacturing development for FTE/FFS capacity of 250 KL+ R&D Facility Facility • Dedicated analytical lab • 50L to 10KL reactor sizes • Equipment o
Slide 14: Consistently Improving: Quality, Safety, Sustainability
Consistently Improving:Quality, Safety, Sustainability ISO 27001:2022, Ecovadis Gold Rating SBTi and ISO 14001:2015, for the third Responsible Care ISO 45001:2018, consecutive year initiated in 2026 ISO 9001:2015 Preparedness and Safety & Environmental Health & Continuous Training Infrastructure Mon
Slide 15: Capital Market Information
Capital Market Information BSE Sensex Vs Innovassynth (ITIL) Share Price 90000 200 85000 150 IIL SHARE PRICE 80000 BSE SENSEX 100 BSE 75000 ITIL 70000 50 65000 0 Oct-25 Nov-25 Dec-25 Jan-26 Feb-26 Mar-26 Apr-26 May-26 Jun-26 Jul-26 Aug-26 Sep-26 Shareholding Pattern (as on 30-Sep-26) FII & Overseas
Slide 16: Thank You
— INN©-VASSYNTH Thank You
Innovassynth Technologies (India) — Q2 FY27 Earnings Presentation on 6ix